Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Cardiology Update from the 2008 ACC Annual Meeting
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
First-line Chemotherapy Options in Metastatic PDAC
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?